Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS (NurOwn)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02017912 |
|
Recruitment Status :
Completed
First Posted : December 23, 2013
Last Update Posted : July 18, 2018
|
Sponsor:
Brainstorm-Cell Therapeutics
Information provided by (Responsible Party):
Brainstorm-Cell Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | March 2016 |
| Actual Study Completion Date : | July 2016 |
| Certification/Extension First Submitted : | July 15, 2018 |